Search
DiaMedica Therapeutics Inc
DMACAdd to Watchlist
6.550USD
+0.400+6.50%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
352.94MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-26The current earnings forecast score of DiaMedica Therapeutics Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 25.00 and a low of 11.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
15.500
Target Price
+152.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
DiaMedica Therapeutics Inc
DMAC
5
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is DiaMedica Therapeutics Inc's price target?
Analysts forecast that DiaMedica Therapeutics Inc's price target is USD 13.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 11.00.
How have DiaMedica Therapeutics IncDMAC's recent earnings per share performed?
The market expectation was USD -0.19, while DiaMedica Therapeutics IncDMAC's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for DiaMedica Therapeutics Inc?
Based on the ratings of DiaMedica Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
